EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Anti-inflammatory Pathways of Novel Anti-diabetic Therapies. A Literature Review

Adina David Comșa, Horațiu Comșa, Gabriel Cismaru, Radu Roșu, Dana Pop

In Vivo · 2026-01 · 40 (1) · 600-627

DOI: 10.21873/invivo.14224 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift In Vivo, online erschienen am 02.01.2026. Verfasst von Adina David Comșa und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Medicine and Pharmacy 'Iuliu Hațieganu', Cluj-Napoca, Romania. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Inflammation, Anti-Inflammatory Agents, Signal Transduction. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SGLT2 inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP-1RAs) are two novel anti-diabetic therapeutic classes with an important impact on cardiovascular outcomes. Ongoing clinical trials are further investigating their potential beneficial effects on multiple cardiovascular conditions. Even though the underlying mechanisms are not yet fully understood, it is speculated that their cardiovascular protection goes beyond simply lowering plasma glucose levels. By reducing chronic inflammation through multiple pathways, these therapeutic agents seem to have pleiotropic effects on the cardiovascular system. This descriptive review summarizes the most important anti-inflammatory pathways of SGLT2 is and GLP1-RAs, as described in present literature. We focus on inflammatory cytokines, oxidative stress, immune cell and mitochondrial function modulation, inflammatory pathway regulation and endothelial dysfunction improvement, with particular emphasis on their role in cardiovascular protection. A better understanding of the molecular mechanisms leading to the beneficial effects of these drugs could be crucial in developing a more specific therapeutic approach to various cardiovascular diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsInflammationAnti-Inflammatory AgentsSignal TransductionHumansSodium-Glucose Transporter 2 InhibitorsAnimalsOxidative StressCardiovascular DiseasesGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

GLP-1 receptor agonistsInflammationSGLT2 inhibitorsatherosclerosiscardiovascularreview

Substanzen

Hypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsAnti-Inflammatory AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • University of Medicine and Pharmacy 'Iuliu Hațieganu', Cluj-Napoca, Romania.
  • University of Medicine and Pharmacy 'Iuliu Hațieganu', Cluj-Napoca, Romania; dh.comsa@gmail.com.
  • Department of Internal Medicine, Faculty of Medicine, University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Department of Cardiology, Rehabilitation Clinical Hospital, Cluj-Napoca, Romania.

Zitieren

APA

Comșa, A. D., Comșa, H., Cismaru, G., Roșu, R., & Pop, D. (2026). Anti-inflammatory Pathways of Novel Anti-diabetic Therapies. A Literature Review. In Vivo, 40(1), 600-627. https://doi.org/10.21873/invivo.14224

Vancouver

Comșa AD, Comșa H, Cismaru G, Roșu R, Pop D. Anti-inflammatory Pathways of Novel Anti-diabetic Therapies. A Literature Review. In Vivo. 2026;40(1):600-627. doi:10.21873/invivo.14224

BibTeX
@article{Coma2026,
  author = {Comșa, Adina David and Comșa, Horațiu and Cismaru, Gabriel and Roșu, Radu and Pop, Dana},
  title = {Anti-inflammatory Pathways of Novel Anti-diabetic Therapies. A Literature Review},
  journal = {In Vivo},
  year = {2026},
  volume = {40},
  number = {1},
  pages = {600--627},
  doi = {10.21873/invivo.14224}
}
Kostenlos starten →